TW201018685A - Pyridopyrimidinone inhibitors of PI3Kα and mTOR - Google Patents

Pyridopyrimidinone inhibitors of PI3Kα and mTOR Download PDF

Info

Publication number
TW201018685A
TW201018685A TW098133017A TW98133017A TW201018685A TW 201018685 A TW201018685 A TW 201018685A TW 098133017 A TW098133017 A TW 098133017A TW 98133017 A TW98133017 A TW 98133017A TW 201018685 A TW201018685 A TW 201018685A
Authority
TW
Taiwan
Prior art keywords
compound
formula
cancer
pharmaceutically acceptable
optionally
Prior art date
Application number
TW098133017A
Other languages
English (en)
Chinese (zh)
Inventor
Tae-Gon Baik
Sung-Hoon Ma
Chris A Buhr
John M Nuss
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of TW201018685A publication Critical patent/TW201018685A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW098133017A 2008-09-30 2009-09-29 Pyridopyrimidinone inhibitors of PI3Kα and mTOR TW201018685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19476108P 2008-09-30 2008-09-30

Publications (1)

Publication Number Publication Date
TW201018685A true TW201018685A (en) 2010-05-16

Family

ID=41572575

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098133017A TW201018685A (en) 2008-09-30 2009-09-29 Pyridopyrimidinone inhibitors of PI3Kα and mTOR

Country Status (8)

Country Link
US (1) US8101622B2 (enExample)
EP (1) EP2350070A1 (enExample)
JP (1) JP2012504628A (enExample)
AR (1) AR073524A1 (enExample)
PA (1) PA8843901A1 (enExample)
TW (1) TW201018685A (enExample)
UY (1) UY32153A (enExample)
WO (1) WO2010039740A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ATE514695T1 (de) 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
CA2683641C (en) * 2007-04-10 2016-08-16 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
CA2828483A1 (en) * 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
KR20140040726A (ko) * 2011-04-29 2014-04-03 엑셀리시스, 인코포레이티드 PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법
PE20141794A1 (es) 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
EP3266455B1 (en) 2015-03-06 2020-12-30 Korea Advanced Institute of Science and Technology Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2020247496A1 (en) 2019-06-04 2020-12-10 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
CN114901664B (zh) * 2020-01-10 2024-07-02 南京再明医药有限公司 吡啶酮化合物及应用
US20230165864A1 (en) * 2020-04-30 2023-06-01 Guangzhou Joyo Pharmatech Co., Ltd Application of heterocyclic compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
AU1808601A (en) 2000-01-27 2001-08-07 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
DZ3308A1 (fr) 2000-03-06 2001-09-27 Warner Lambert Co Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
ATE514695T1 (de) * 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
BRPI0810175A2 (pt) * 2007-04-11 2014-12-30 Exelixis Inc Inibidores pirididopirinidinona de p13k alfa

Also Published As

Publication number Publication date
WO2010039740A1 (en) 2010-04-08
PA8843901A1 (es) 2010-05-26
AR073524A1 (es) 2010-11-10
JP2012504628A (ja) 2012-02-23
US20100087456A1 (en) 2010-04-08
US8101622B2 (en) 2012-01-24
UY32153A (es) 2011-04-29
EP2350070A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
TW201018685A (en) Pyridopyrimidinone inhibitors of PI3Kα and mTOR
EP2771342B1 (en) Purine derivatives and their use in the treatment of disease
JP4344607B2 (ja) 蛋白キナーゼ阻害剤としてのピロロピリミジン
JP5963777B2 (ja) 新規ヘテロ環誘導体
JP6649540B2 (ja) 置換されたヘテロアリール化合物および使用方法
CN113861188B (zh) 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用
TW201815799A (zh) 巨環激酶抑制劑
JP2010518107A (ja) Ｐｉ３−キナーゼ阻害剤およびその使用方法
US11304929B2 (en) Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
JPWO2004043936A1 (ja) Ｐｌｋ阻害剤
TW201144318A (en) Activators of AMPK and therapeutic uses thereof
TW201014841A (en) Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors
TWI458730B (zh) 新穎２，３－二氫－１Ｈ－咪唑并｛１，２－ａ｝嘧啶－５－酮衍生物，其製法及其醫藥用途
TW200845997A (en) 2-substituted-6-heterocyclic pyrimidone derivatives
JP2021503479A (ja) 置換ヘテロアリール化合物及び使用方法
TW201105673A (en) Novel 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof
CN110872296A (zh) 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
WO2022007921A1 (zh) 三嗪类化合物及其组合物和用途
CN116947764A (zh) 一种嘧啶胺类nuak抑制剂及其制备方法和用途
JP2008536938A (ja) Ａｋｔ活性の阻害物質
JP2018527340A (ja) アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
WO2012083145A1 (en) Glucosamine derivatives
CN103384667A (zh) 作为PI3K/mTOR抑制剂的苯并氧氮杂卓及其使用和生产方法
TW202448451A (zh) 新穎噻吩并［３，２—ｂ］吡啶衍生物
TW202304908A (zh) 四氫吡啶并嘧啶化合物